Na het succes van vorig jaar en als extraatje voor de leden die ook als exposant deelnemen aan de beurs, staat onze exclusieve netwerkavond, Connecting@LABORAMA, opnieuw op de agenda tijdens editie 2023.
Leden/exposanten krijgen de extra mogelijkheid om, dankzij dit evenement, beleidsmakers aan te trekken naar de beurs.
Het verloop van de avond:
- Nodig de beleidsmakers binnen uw cliënteel uit op 16 maart 2023 in de namiddag
- 16u30 - einde van de beursdag gevolgd door een aperitief in de foyer van Paleis 3*
Exclusief voor leden/exposanten en hun gasten**:
- 17u30 - Ontvangst in de Conference Room van Paleis 3 + welcome speech
- 17u45 - Voorgerecht
- 18u15 - Keynote by Liesbet Lagae (IMEC) - "Analyze the patient, engineer the therapy"
- 18u45 - Hoofdgerecht
- 19u15 - Comedy by Christophe Deborsu & Annick De Wit
- 20u00 - Dessert + Koffie
- 21u00 - verwacht einde
* Aperitief toegankelijk voor alle exposanten.
** Deelname aan het netwerkevent bedraagt voor leden/exposanten en hun gasten €60 p.p.
Inschrijven is mogelijk via het online beursbezoek.
Keynote "Analyze the patient, engineer the therapy" door Liesbet Lagae, IMEC
The exponential growth of the semiconductor industry has shown value for consumers by increasing performance while scaling down the cost. The result of that is the highest standard in precision and volume production of nanoelectronics based chip and sensor solutions. Over the past 10 years, Imec has used their experience in semiconductor process and design technologies for building out a health oriented activity that uses single use silicon biochips and microfluidics for DNA sequencing, cell sorting, DNA synthesis, single cell gene editing and biosensing.
These chip solutions have until now mainly served the diagnostic market. But we need to go further, similar technology building blocks can solve challenges in personalized healthcare by following trajectories of individual patients and by adapting the therapies. The latest generation of therapies uses not only individual information from the patient, but also patient material such as immune cells from the patient, to build powerful new types of personalized treatments. These innovative therapies come with very new challenges in relation to cost, logistics and quality, and todays lab infrastructure and healthcare system is not adapted for this. We will explain how chip miniaturization can help to overcome important challenges along the healthcare cycle in order to give patient access to affordable, more personalized and adapted treatments and save lives.
Liesbet Lagae - Bio
Liesbet Lagae, Ms. E. E., Phd, is IMEC fellow and currently program director of IMEC Life sciences. In this role, Liesbet is the scientific leader of a multidisciplinary team of > 50 researchers working on miniaturization of biochips, microfluidics and integration of bio-assays. By leveraging those chip-based sensor solutions, she builds the tools for next generation sequencing, cytometry, cell sorting, genomics, implantables and bioreactors.
Liesbet Lagae (born 1975, Leuven, Belgium) received her PhD degree from the KU Leuven, Belgium for her work on Magnetic Random Access Memories in 2003. She has pioneered life science technologies based on silicon based biochips at IMEC, Belgium. She created a successfully growing business line how smart silicon biochips could be tailored to the needs of our customers in the medical community. She was appointed as a KULeuven part time professor in nanobiophysics as a consequence of these early-carreer achievements.
Liesbet has (co-) authored more than 300 publications. She holds 16 patents in the field. She coordinated several EU and regional projects. She holds a prestigious ERC Consolidator Grant that deals with an innovative cell sorter-on-chip technology. She is or has been promotor of > 20 PhD students.